BIOINVENT FINANCIAL STATEMENT 1 JANUARY-31 DECEMBER 2003

BIOINVENT FINANCIAL STATEMENT 1 JANUARY-31 DECEMBER 2003 * Promising pre-clinical data for BioInvent's HIV project: The Company's antibodies against HIV are effectively preventing the spread of the virus between human cells. * Progress within BioInvent's atherosclerosis treatment project: Antibodies tested in pre-clinical animal models indicate a clear reduction in plaque in the blood vessels. * Project portfolio strengthened: Drug projects initiated for the treatment of widespread diseases such as cancer and osteoarthritis according to new therapeutic principles. * Cross-licensing agreement regarding antibody technologies signed with XOMA, a US pharmaceutical company. * Patent portfolio strengthened: European patent granted for the n-CoDeR antibody library. * Net revenues for January - December 2003: SEK 66.7 million (87.1) * Cash flow from current operations and investment activities for January - December 2003: SEK -75.5 million (-47.1). Liquid funds at the end of the year: SEK 268.5 million (343.6). * Loss after net financial items for January - December 2003 amounted to SEK -89.7 million (-46,2) and the loss after net financial items per share was SEK -3.04 (1.60). Contact: Any questions regarding this report will be answered by: Svein Mathisen, President & CEO, tel.+46 (0)46 286 85 67, mobile +46 (0)708 97 82 13 or Cristina Glad, Executive Vice President, +46 (0)46 286 85 51, mobile +46 (0)708 16 85 70. The report is also available at www.bioinvent.com BioInvent International AB (publ.) Co. reg. no. 556537-7263 Address: Sölvegatan 41, 223 70 Lund Tel.: +46 (0)46 286 85 50 info@bioinvent.com www.bioinvent.com Legal disclaimer This press release contains statements relating to future scenarios. Research and development activity within the biotech field is associated with risk and/or uncertainty. With this in mind, the actual outcome may deviate significantly from what is described in this press release. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/06/02/20040602BIT00370/wkr0001.doc The full report http://www.waymaker.net/bitonline/2004/06/02/20040602BIT00370/wkr0002.pdf The full report

About Us

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The antibody library n-CoDeR and the screening tool F.I.R.S.T. are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

Subscribe